Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanofi protein-based pneumococcal vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
The Sanofi protein-based pneumococcal vaccine (PPrV) is an investigational vaccine candidate developed by Sanofi Pasteur for the prevention of infections caused by *Streptococcus pneumoniae*. Unlike traditional pneumococcal conjugate vaccines (PCVs) that target the polysaccharide capsule of specific serotypes, the PPrV approach utilizes highly conserved surface proteins to provide broader, serotype-independent protection. The primary antigens in these formulations typically include the Pneumococcal histidine triad protein D (PhtD) and a detoxified version of pneumolysin (dPly). These proteins are essential for the virulence and colonization of the bacteria across most known serotypes. Sanofi has evaluated several versions of this vaccine, such as SP0125 and SP0148, in Phase 1 and Phase 2 clinical trials to assess their safety and ability to induce a robust immune response in healthy adults and pediatric populations.
- Other names
- Sanofi PPrVInvestigational Protein-based Pneumococcal Vaccine
02
Targets
PcpA (Pneumococcal choline-binding protein A)PhtD (Pneumococcal histidine triad protein D)Ply (Pneumolysin)
Beyond the preview
Go deeper on Sanofi protein-based pneumococcal vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sanofi protein-based pneumococcal vaccine.